Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
|
By LabMedica International staff writers Posted on 24 Jun 2021 |

Image: VITROS® Automation Solutions (Photo courtesy of Ortho Clinical Diagnostics)
Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its wide range of VITROS diagnostic testing and automation solutions at MEDLAB Middle East 2021.
Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.
Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.
Related Links:
Ortho Clinical Diagnostics
Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.
Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.
Related Links:
Ortho Clinical Diagnostics
Latest MEDLAB 2021 News
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, with more than 60% of cases still diagnosed at a late stage. Uptake of existing screening tools remains suboptimal,... Read more
Automated NfL Assay Supports Monitoring of Neurological Disorders
Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. Blood-based measurement of neurofilament light chain (NfL) provides a biologically... Read moreMolecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more





.jpg)



